IDBiologics is a private biopharmaceutical company focused on the discovery and development of human monoclonal antibodies (mAbs) for the prevention and treatment of infectious diseases. IDBiologics is developing a clinical candidate to address both seasonal (H1 and H3) and pre-pandemic strains of influenza (H5, H7, H9). Beyond Pan-Influenza (seasonal prophylaxis against Flu A & B), the Company’s pipeline includes clinical lead mAbs targeting the BK virus, Respiratory Syncytial virus / metapneumovirus combination (RSV/MPV), Zika virus, Rift Valley Fever virus and Enterovirus D68. The Company has a sponsored research agreement with its co-founder, Dr. James E. Crowe, and his laboratory at the Vanderbilt University Medical Center (VUMC). Our innovative fully human mAb platform enables rapid discovery and optimization of broad and potent mAbs with neutralizing activity to a range of viral targets.


Coalition to Stop Flu Chairman Former Sen. Tom Daschle Quoted in Endpoints News

National Academy of Medicine: “An effective pandemic preparedness and response system is possible”